Rheumatologists Favor First Tracks’ Rosnilimab as Next-Gen RA Therapy
Event summary
- Spherix Global Insights survey of 103 U.S. rheumatologists (July 30–August 5, 2026) highlights strong physician interest in First Tracks Biotherapeutics’ rosnilimab for rheumatoid arthritis (RA).
- Nearly one-third of physicians rate rosnilimab as a substantial advance over current RA treatments, the highest among pipeline therapies evaluated.
- Physicians estimate 16% of RA patients are refractory to treatment, underscoring unmet needs in difficult-to-treat populations.
- Sanofi’s oral TNF inhibitor balinatunfib generated strong physician interest despite its discontinuation on July 30, 2026.
The big picture
The RA market is evolving with biosimilars and generics intensifying price pressure on legacy brands, while newer mechanisms like JAK inhibitors gain traction. Physician enthusiasm for pipeline therapies like rosnilimab suggests a demand for tangible clinical advances, particularly for refractory patients. The challenge for new entrants will be differentiating in a market where cost and established preferences are significant barriers.
What we're watching
- Pipeline Differentiation
- Whether rosnilimab and imeroprubart can sustain physician enthusiasm through clinical trial results and regulatory approvals.
- Market Competition
- How biosimilars and established therapies like AbbVie’s Rinvoq will impact adoption of next-gen RA treatments.
- Treatment Innovation
- The pace at which novel mechanisms address refractory and difficult-to-treat RA populations.